Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma-Reference-Cited by-同舟云学术

Abstract CT188: 5-year survival and other long-term outcomes from KEYNOTE-006 study of pembrolizumab (pembro) for ipilimumab (ipi)-naive advanced melanoma

Published:2019-07-01 Issue: Volume: Page:
ISSN:
Container-title:Clinical Trials
language:
Short-container-title:

Author:

Robert Caroline,Schachter Jacob,Long Georgina V.,Arance Ana,Grob Jean-Jacques,Mortier Laurent,Daud Adil,Carlino Matteo S.,McNeil Catriona,Lotem Michal,Larkin James,Lorigan Paul,Neyns Bart,Blank Christian U.,Hamid Omid,Petrella Teresa M.,Anderson James,Krepler Clemens,Diede Scott J.,Ribas Antoni

Publisher

American Association for Cancer Research

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and economic analysis of treatment sequences with prolgolimab and BRAF/MEK inhibitors in adult patients with metastatic or unresectable cutaneous melanoma;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2023-12-30

2. Systemic Therapy for Melanoma: ASCO Guideline Update;Journal of Clinical Oncology;2023-10-20

3. Demographics, Pattern of Care, and Outcome Analysis of Malignant Melanomas - Experience From a Tertiary Cancer Centre in India;Frontiers in Oncology;2021-09-08

4. Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study;Annals of Oncology;2021-03

5. Porównanie pośrednie wyników leczenia chorych na zaawansowane/przerzutowe czerniaki za pomocą niwolumabu lub pembrolizumabu – analiza wieloośrodkowa;Oncology in Clinical Practice;2020-10-29